Peter Heerma Travere Therapeutics, Inc. (TVTX) insider trading activity

TVTX Quotes by TradingView

Peter Heerma is CHIEF COMMERCIAL OFFICER of Travere Therapeutics, Inc.. Currently has a direct ownership of 107,958 shares of TVTX, which is worth approximately $1.97 Million. The most recent transaction as insider was on Sep 09, 2024, when has been sold 2,191 shares (Common Stock) at a price of $11.52 per share, resulting in proceeds of $25,240. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 108K
8.5% 3M change
34.52% 12M change
Total Value Held $1.97 Million

Peter Heerma Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 09 2024
SELL
Open market or private sale
$25,240 $11.52 p/Share
2,191 Reduced 1.99%
107,958 Common Stock
Sep 05 2024
BUY
Grant, award, or other acquisition
-
6,750 Added 5.77%
110,149 Common Stock
Feb 01 2024
SELL
Open market or private sale
$35,783 $8.53 p/Share
4,195 Reduced 4.05%
99,503 Common Stock
Jan 31 2024
BUY
Grant, award, or other acquisition
-
25,000 Added 19.43%
103,698 Common Stock
Jan 23 2024
SELL
Open market or private sale
$14,140 $9.07 p/Share
1,559 Reduced 1.94%
78,698 Common Stock
Oct 03 2023
SELL
Open market or private sale
$25,500 $8.25 p/Share
3,091 Reduced 3.71%
80,257 Common Stock
Feb 01 2023
SELL
Open market or private sale
$38,693 $21.75 p/Share
1,779 Reduced 2.12%
82,069 Common Stock
Jan 31 2023
BUY
Grant, award, or other acquisition
-
20,250 Added 19.45%
83,848 Common Stock
Jan 24 2023
SELL
Open market or private sale
$33,945 $21.9 p/Share
1,550 Reduced 2.38%
63,598 Common Stock
Jan 31 2022
SELL
Open market or private sale
$30,825 $27.4 p/Share
1,125 Reduced 1.64%
67,297 Common Stock
Jan 31 2022
BUY
Grant, award, or other acquisition
-
9,840 Added 12.57%
68,422 Common Stock
Jan 24 2022
SELL
Open market or private sale
$46,837 $24.98 p/Share
1,875 Reduced 3.1%
58,582 Common Stock
Oct 04 2021
SELL
Open market or private sale
$75,747 $24.77 p/Share
3,058 Reduced 4.81%
60,457 Common Stock
Aug 17 2021
SELL
Open market or private sale
$24,088 $17.12 p/Share
1,407 Reduced 2.17%
63,515 Common Stock
Aug 13 2021
BUY
Grant, award, or other acquisition
-
4,500 Added 6.48%
64,922 Common Stock
Feb 08 2021
SELL
Open market or private sale
$35,527 $31.58 p/Share
1,125 Reduced 1.86%
59,344 Common Stock
Feb 05 2021
SELL
Open market or private sale
$35,336 $31.41 p/Share
1,125 Reduced 1.83%
60,469 Common Stock
Feb 03 2021
SELL
Open market or private sale
$16,276 $28.91 p/Share
563 Reduced 0.98%
57,094 Common Stock
Feb 03 2021
BUY
Grant, award, or other acquisition
-
4,500 Added 6.81%
61,594 Common Stock
Feb 02 2021
SELL
Open market or private sale
$17,312 $30.75 p/Share
563 Reduced 0.97%
57,657 Common Stock
Jan 21 2021
BUY
Grant, award, or other acquisition
-
15,000 Added 20.49%
58,220 Common Stock
Oct 05 2020
SELL
Open market or private sale
$42,338 $19.35 p/Share
2,188 Reduced 4.91%
42,329 Common Stock
Oct 02 2020
SELL
Open market or private sale
$41,353 $18.9 p/Share
2,188 Reduced 4.68%
44,517 Common Stock
PH

Peter Heerma

CHIEF COMMERCIAL OFFICER
San Diego, CA

Track Institutional and Insider Activities on TVTX

Follow Travere Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TVTX shares.

Notify only if

Insider Trading

Get notified when an Travere Therapeutics, Inc. insider buys or sells TVTX shares.

Notify only if

News

Receive news related to Travere Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on TVTX